Vimarsana
Biggest News Aggregation in the World

Greer Lab News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Greer Lab. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Greer Lab Today - Breaking & Trending Today

New Study Uncovers Biological Mechanism Behind Loss of Smell in Parkinson's Patients < Neurosurgery - Vimarsana News

New Study Uncovers Biological Mechanism Behind Loss of Smell in Parkinson's Patients < Neurosurgery

In a new study published in Journal of Neuroscience, researchers uncover the biological mechanism behind loss of smell in Parkinson's patients.

Source: yale.edu
Fourth Circuit Rejects FCA Claims On Scienter Grounds Based On Ambiguous Regulations - Food, Drugs, Healthcare, Life Sciences - Vimarsana News

Fourth Circuit Rejects FCA Claims On Scienter Grounds Based On Ambiguous Regulations - Food, Drugs, Healthcare, Life Sciences

In Short The Situation: Manufacturers of allergenic extracts that are injected into a patient must obtain a Food and Drug Administration ("FDA") approved license in order to ensure their products are safe for consumption. Until the FDA issued regulatory guidance in 2015, most manufacturers interpreted the FDA regulation at issue as allowing a general license for the custom mixes of extracts. But the FDA's 2015 guidance clarified that a separate license was required for custom mixes. Seizing on the guidance, relators have sought False Claims Act ("FCA") liability for earlier claims that do no...

Source: mondaq.com
Fourth Circuit Rejects FCA Claims on Scienter Grounds Based on Ambiguous Regulations | Jones Day - Vimarsana News

Fourth Circuit Rejects FCA Claims on Scienter Grounds Based on Ambiguous Regulations | Jones Day

In Short The Situation: Manufacturers of allergenic extracts that are injected into a patient must obtain a Food and Drug Administration ("FDA") approved license in order to ensure their products are safe for consumption. Until the FDA issued regulatory guidance in 2015, most manufacturers interpreted the FDA regulation at issue as allowing a general license for the custom mixes of extracts. But the FDA's 2015 guidance clarified that a separate license was required for custom mixes. Seizing on the guidance, relators have sought False Claims Act ("FCA") liability for earlier claims that do not...